XRN earnings analysis
What we found in XRN's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The provided 10-Q extract does not include the income statement, balance sheet, cash-flow statement, MD&A, or segment results, so revenue, margins, EPS, working-capital trends and free cash flow cannot be assessed from the filing text supplied. The filing does show $96.8 million of net Series C proceeds used with cash and Credit Facility borrowings to fund acquisitions, but also highlights $141.0 million of unhedged variable-rate debt and approximately $1.4 million of annual cash-flow sensitivity per 100-basis-point SOFR increase. Sentiment is neutral because capital availability is positive but operating and financing risks are material and quarterly earnings trends are unavailable.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- $96.8M net preferred-equity proceeds
- The company completed a private placement of 1,000,000 shares of 6.00% Series C Convertible Preferred Stock for aggregate gross proceeds of $100.0 million and received approximately $96.8 million net of fees and expenses. Proceeds, cash on hand and Credit Facility borrowings funded acquisitions of the Landing and the Riviera.
- Capital raised for acquisitions
- As of June 30, 2026, the company had $141.0 million of unhedged variable-rate Revolver borrowings outstanding. The filing states that SOFR was 3.65% on June 30, 2026.
- Controls assessed effective
- Management states that disclosure controls and procedures were effective as of June 30, 2026, at a reasonable assurance level. The filing also reports no changes to internal control over financial reporting during the quarter that materially affected, or were reasonably likely to materially affect, those controls.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Material floating-rate exposure
- The company had $141.0 million of unhedged variable-rate borrowings as of June 30, 2026. A 100-basis-point increase in SOFR would decrease annual cash flow by approximately $1.4 million, assuming no increase in variable-rate debt.
- Convertible preferred dilution
- The Series C financing creates potential future common-stock dilution: 1,000,000 preferred shares are initially convertible at a rate of 2.32558 common shares per preferred share, based on an implied conversion price of $43.00 per common share. The preferred issuance generated $100.0 million of gross proceeds.
- Expanded SHOP operating exposure
- The 10-Q identifies new or expanded SHOP-related operational, licensing, manager-transition and litigation risks compared with the 2025 Annual Report, while stating that otherwise there were no material risk-factor changes. The company holds applicable healthcare licenses and may face penalties including loss or suspension of licenses, reimbursement denial or facility closure.
What they said about what is next.
The provided 10-Q extract does not include quantitative revenue or EPS guidance. No explicit numeric outlook is disclosed; guidance may have been provided in the earnings release or call.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 7, 2026
- Chiron Real Estate Inc. reported Q1 2026 results with strong earnings, boasting an EPS of $1.11, surpassing estimates significantly, while revenues slightly fell short of expectations at $38.02 million. Notably, the…
- 10-K · March 2, 2026
- Chiron Real Estate (formerly Global Medical REIT) positions itself as a focused healthcare REIT investing in off‑campus and small-to-mid-sized medical facilities with a stated goal of delivering attractive dividends and…
- 10-Q · May 8, 2025
- Global Medical REIT reported Q1 2025 total revenue of $34,618 (down from $35,118 in Q1 2024) and net income attributable to common stockholders of $2,104 (Q1 2024: $794), or $0.03 per share (Q1 2024: $0.01). Operating…
- 10-K · February 28, 2025
- Global Medical REIT’s 2024 10-K emphasizes a strategy focused on decentralized healthcare real estate (primarily medical office buildings) and opportunistic investments while highlighting a new joint venture with…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing XRN makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever